GlassScriptPhysician profile
Emily E Carey
NPI 1265656870
$2,020.11
in general payments reported to CMS, 2019-2025
24 companies · $1,098 in 2025
The $1,098 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $158 · 2021: $48.33 · 2022: $95.25 · 2023: $355 · 2024: $266 · 2025: $1,098.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.54 | 2020-2025 | Skyrizi, Rinvoq, Humira |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $179.22 | 2020-2025 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $127.17 | 2023-2025 | Entyvio |
| Neuraxis, INC. | $107.51 | 2025 | |
| Pfizer INC. | $101.42 | 2025 | |
| Genzyme Corporation | $94.36 | 2025 | |
| Lilly USA, LLC | $65.34 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $53.83 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $51.66 | 2025 | Wegovy |
| Qol Medical, LLC | $46.07 | 2023-2025 | Sucraid |
| Janssen Biotech, INC. | $41.68 | 2024 | Tremfya |
| Celgene Corporation | $40.26 | 2023-2024 | Zeposia |
| Braintree Laboratories, INC. | $33.17 | 2020-2025 | Suflave, Sutab |
| Vivus LLC | $33.00 | 2025 | Qsymia |
| Ironwood Pharmaceuticals, INC | $28.96 | 2020-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $28.75 | 2023 | |
| Ardelyx, INC. | $28.18 | 2023-2024 | Ibsrela |
| Madrigal Pharmaceuticals | $27.04 | 2025 | Rezdiffra |
| Caris Mpi, INC. | $22.22 | 2025 | Mi Cancer Seek |
| Ferring Pharmaceuticals INC. | $18.31 | 2025 | Rebyota |
| Stryker Corporation | $17.99 | 2025 | Neptune |
| Sandoz INC. | $17.25 | 2025 | Hyrimoz |
| Azurity Pharmaceuticals, INC. | $14.18 | 2025 | Sutab |
| Echosens North America, INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Carey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.